Table 3.

Multivariate Logistic Regression Results for Receipt of Adjuvant FU-Based Chemotherapy and Surveillance Colonoscopy

Variable	Adjuvant FU Chemotherapy* (n = 653)			Surveillance Colonoscopy (n = 2006)
	OR	95% CI	P	OR	95% CI	P
Demographic
White	1.23	0.77 to 1.97	.40	1.32	1.01 to 1.73	.04
Married	1.30	0.90 to 1.88	.16	1.00	0.82 to 1.22	1.00
Age at diagnosis, years
< 55	1.70	0.86 to 3.38	.13	1.12	0.77 to 1.62	.55
55-64	1.03	0.65 to 1.62	.91	1.20	0.93 to 1.53	.16
65-74	1.15	0.71 to 1.87	.57	1.47	1.14 to 1.89	< .01†
75+ (referent)
Region
North	1.75	1.00 to 3.07	.05	1.28	0.96 to 1.71	.09
Central	1.52	0.95 to 2.42	.08	0.84	0.65 to 1.08	.18
West	1.30	0.79 to 2.14	.31	1.01	0.77 to 1.33	.93
South (referent)
Comorbidity
Liver disease	0.28	0.04 to 2.11	.22	—‡
Rheumatoid disease or AIDS	1.11	0.20 to 6.17	.90	1.00	0.40 to 2.46	.99
Renal disease	0.68	0.22 to 2.14	.51	0.87	0.49 to 1.56	.65
Dementia or paralysis	0.17	0.01 to 2.03	.16	—§
CHF, acute MI, CVD, or COPD	0.82	0.53 to 1.25	.35	0.84	0.67 to 1.06	.14
Diabetes	0.84	0.56 to 1.26	.40	0.86	0.69 to 1.08	.20
Stage at diagnosis
I				0.71	0.56 to 0.90	< .01†
II (referent)
III				0.97	0.77 to 1.24	.83

Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FU, fluorouracil; MI, myocardial infarction; OR, odds ratio.

^*Stage is not included because only patients with stage III colorectal cancer were included per National Comprehensive Cancer Network guidelines.

^†Indicates statistical significance of P < .01.

^‡Because of issues of perfect prediction with liver disease, 11 observations were excluded.

^§Because of perfect prediction with dementia/paralysis, five observations were excluded.